Perinatal depression prevalence in Ethiopian women ranges from 20.1% to 25.8% based on pooled meta-analysis data.

This study functions as an umbrella review and meta-analysis focusing on the prevalence of perinatal depressive symptoms among women in Ethiopia. The analysis synthesized data from a total sample size of 15,592 participants. The setting was specifically identified as Ethiopia, encompassing women across various perinatal contexts. The primary outcome measured was the pooled prevalence of perinatal depressive symptoms. Secondary outcomes included specific prevalence rates for antenatal and postnatal depressive symptoms. The review did not report a specific intervention or comparator, nor did it report a specific follow-up duration for the aggregated data.

The primary outcome results indicated a pooled prevalence of perinatal depressive symptoms ranging from 20.1% to 25.8%. The calculated effect size for the pooled prevalence was 22.49%, with a 95% confidence interval of 21.38 to 23.59. When analyzing specific symptom timing, the prevalence of antenatal depressive symptoms was 22.76% (95% CI: 19.9, 25.62). The prevalence of postnatal depressive symptoms was 21.75% (95% CI: 21.03, 22.48). Subgroup analysis based on the number of primary studies yielded a pooled prevalence of 22.86% (95% CI: 20.39, 25.33) for studies with 10 or fewer primary studies, and 22.10% (95% CI: 21.55, 22.65) for studies with fewer than 10 primary studies. No p-values were reported for these specific subgroup comparisons in the provided data.

Safety and tolerability findings were not reported in this review. Adverse events, serious adverse events, discontinuations, and overall tolerability were not assessed or disclosed. This is consistent with the nature of a prevalence study rather than a clinical trial evaluating a specific treatment. The study did not report funding sources or potential conflicts of interest.

Methodological limitations were explicitly noted. Four of the included studies demonstrated high methodological quality, while the remaining four relied on a moderate quality range. A very high degree of overlap of primary studies was observed among the included systematic reviews and meta-analysis studies, resulting in a corrected covered area (CCA) of 25.5%. This overlap suggests potential duplication of data sources, which may influence the precision of the estimates. The heterogeneity in included studies further complicates the interpretation of the pooled data.

These results compare to prior landmark studies by providing a specific, aggregated view of the burden within the Ethiopian context, where such data may be sparse. However, the lack of intervention data means these results cannot be directly compared to efficacy trials of antidepressants or psychotherapy. The findings underscore the need for targeted strategies to alleviate this mental health challenge, guiding policymakers and health practitioners. The practice relevance lies in establishing a baseline prevalence to inform resource allocation and screening protocols in low-resource settings.

Several questions remain unanswered. The specific diagnostic criteria used across the included studies were not detailed in the provided data, which may contribute to the observed heterogeneity. The demographic characteristics of the women included, such as age, parity, or socioeconomic status, were not reported. Furthermore, the specific healthcare settings within Ethiopia where data were collected were not detailed, limiting the ability to assess urban versus rural disparities. The long-term outcomes of these depressive symptoms were not reported, leaving the trajectory of perinatal depression in this population unclear. Clinicians must interpret these prevalence estimates with caution, recognizing they do not represent a causal relationship or a specific treatment effect.